{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to the low number of events","groupId":"OG000","lowerLimit":"9.00","upperLimit":"NA","value":"104.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"Duration of response is defined as the number of days from the first day of corrected serum calcium ≤ 11.5 mg/dL (2.9 millimoles/L) to the last day of corrected serum calcium ≤ 11.5 mg/dL. Participants were censored on the last CSC assessment day if their CSC level never reached \\> 11.5 mg/dL after the first response. If a participant had no CSC assessment after the first response, duration of response was set to zero and censored. Duration of response was summarized for participants who achieved a response using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study Days 8 and 15.","id":"OG000","title":"Denosumab"}],"paramType":"MEDIAN","populationDescription":"Participants with a response in the Response Analysis Subset","reportingStatus":"POSTED","timeFrame":"From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months.","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"days"}